Lipid Disorders
Conference Coverage
Obesity phenotyping matches patients with more effective interventions
A prospective, randomized study suggests obesity phenotyping can guide selection of more effective, tailored weight-loss drug regimens.
From the Journals
New AHA scientific statement on menopause and CVD risk
An AHA scientific statement aims to raise awareness of healthcare providers and women about the menopause transition as a time of increasing heart...
From the Journals
New study pinpoints how Mediterranean diet reduces diabetes risk
Health care professionals should recognize the importance of weight loss in those older than 60 years and include them in programs to treat...
From the Journals
Statins beneficial in elderly, guidelines should be strengthened
“These findings support the concept of the cumulative burden of LDL cholesterol over one’s lifetime and the progressive increase in risk for...
Conference Coverage
Liquid biopsy captures key NASH pathology hallmarks
Scanning for key proteins in serum identified fibrosis, inflammation, hepatocyte ballooning, and steatosis with high accuracy.
Conference Coverage
SAMSON pins most muscle pain experienced with statins on the nocebo effect
Some patients really do get side effects, such as muscle pain, from statins, but the trial suggests that “90% of this symptomatic burden is...
Conference Coverage
Evinacumab, novel lipid-lowerer, extends promise in phase 2 results
Evinacumab cuts LDL-C and triglycerides by boosting lipase activity. It showed safety and efficacy in patients with heterozygous FH.
Conference Coverage
Chronic inflammatory diseases vary widely in CHD risk
The highest coronary heart disease risks linked to inflammation are seen in SLE and systemic sclerosis, conditions that aren’t included in...
Conference Coverage
SCAPIS: Simple questionnaire can identify silent atherosclerosis
The study found 40% of the middle-aged Swedish population without known heart disease had coronary plaques on CCTA, and those with extensive...
Conference Coverage
GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit
From the Journals
Lipid profiles distinguish obese and nonobese NAFLD patients
Distinct lipid combinations showed noninvasive predictive potential for both obese and nonobese nonalcoholic fatty liver disease patients.